Free Valet Parking

Doylestown Hospital will provide complimentary valet services Monday – Friday from 7 am – 5 pm for patients and visitors. Learn more

Cancer Clinical Trials and Research Programs

Doylestown Health's Cancer Institute is a member of the Eastern Cooperative Oncology Group (ECOG), one of the largest clinical cancer research organizations in the United States, and conducts clinical trials in all types of adult cancers. ECOG is funded by the National Cancer Institute (NCI), part of the National Institutes of Health (NIH).

Doylestown Health conducts research and clinical trials in collaboration with Thomas Jefferson's Sidney Kimmel Cancer Network. Our cancer care team is proud to offer local patients the most current opportunities and the convenience of participating in these vitally important cancer research programs close to home.

Contact

Peggy Hughes, RN, BSN, OCN
Clinical Trial Nurse Coordinator
215-345-2378
MHughes2@dh.org

Doylestown Health is currently enrolling patients in the following approved oncology protocols:

Breast

A011401

  • Phase III Randomized Trial
  • Breast Cancer Weight Loss Study (BWEL Study)
  • Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Stage Breast Cancer

NRG-BR003

  • A randomized phase III trial of adjuvant chemotherapy comparing doxorubicin plus cyclophosphamide followed by weekly paclitaxel with or without carboplatin for node-positive or high-risk node negative, triple negative invasive breast cancer.

A011502

  • Phase III Randomized Trial
  • Evaluates the effect of aspirin vs placebo on the rate of breast cancer recurrence

Metastatic Cancer

EAY131 MATCH

  • Molecular Analysis for Therapy Choice
  • Non-randomized phase II “basket” trial
  • Requires biopsy of tumor

Genetics

Cancer Genetics and Risk Registry

  • To learn more about inherited cancer risk, familial cancers, and genetic mutations predisposing to cancer
  • Open to adults who have been diagnosed with any type of cancer
  • Open to adults with a family history of cancer

Rare Tumors

S1609 DART

  • Dual Anti-CTLA4 and Anti-PD-1 Blockade in rare tumors (Combination Opdivo plus Yervoy).

Prostate Cancer

IRONMAN

  • A non-therapeutic international registry to describe the practice patterns of therapeutic agents for advance prostate cancer, to identify associations between treatment sequences or combinations and overall survival, to define the patient experience and identify unmet needs in their treatment, and to identify clinical and molecular disease subtypes that predict response to individual treatments, combinations or sequences.

Genetic Evaluation of Men (GEM)

  • Open to men with prostate cancer or unaffected men at higher risk for prostate cancer
  • Genetic testing for prostate cancer if eligible

For more information about Doylestown Health's open cancer trials visit the U.S. National Institutes of Health's Clinical Trials database. Learn more about clinical trials.

Learn More

Show more Show less